DESIGN THERAPEUTICS INC (DSGN) Stock Price, Quote, News and Overview
NASDAQ:DSGN - Nasdaq - US25056L1035 - Common Stock - Currency: USD
DSGN Quote, Performance and Key Statistics
DESIGN THERAPEUTICS INC
NASDAQ:DSGN (2/10/2025, 8:00:01 PM)
Premarket: 4.35 +0.09 (+2.11%)4.26
-0.03 (-0.7%)
The current stock price of DSGN is 4.26 USD. In the past month the price decreased by -5.75%. In the past year, price increased by 61.98%.
DSGN Latest News and Analysis
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing...
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
DSGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.81 | 336.36B | ||
| AMGN | AMGEN INC | 14.87 | 158.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1620.59 | 121.03B | ||
| GILD | GILEAD SCIENCES INC | 21.55 | 118.99B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.86B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.35B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.41B | ||
| NTRA | NATERA INC | N/A | 22.73B | ||
| BIIB | BIOGEN INC | 8.73 | 20.77B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.18 | 15.43B |
Related stock screener links
About DSGN
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 54 full-time employees. The company went IPO on 2021-03-26. The company is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The firm is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Company Info
DESIGN THERAPEUTICS INC
6005 Hidden Valley Road, Suite 110
Carlsbad CALIFORNIA 92011 US
CEO: Joao Siffert
Employees: 57
Company Website: https://www.designtx.com/
Investor Relations: https://investors.designtx.com/
Phone: 18582934900
DSGN FAQ
What is the stock price of DSGN?
The current stock price of DSGN is 4.26 USD.
What is the symbol for DESIGN THERAPEUTICS INC stock?
The exchange symbol of DESIGN THERAPEUTICS INC is DSGN and it is listed on the Nasdaq exchange.
On which exchange is DSGN stock listed?
DSGN stock is listed on the Nasdaq exchange.
Is DSGN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for DSGN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of DSGN.
Does DSGN stock pay dividends?
DSGN does not pay a dividend.
When does DSGN stock report earnings?
DSGN will report earnings on 2025-03-06, after the market close.
What is the Price/Earnings (PE) ratio of DSGN?
DSGN does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.85).
What is the Short Interest ratio of DSGN stock?
The outstanding short interest for DSGN is 9.1% of its float.
DSGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DSGN. When comparing the yearly performance of all stocks, DSGN is one of the better performing stocks in the market, outperforming 81.44% of all stocks.
DSGN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DSGN. While DSGN has a great health rating, there are worries on its profitability.
DSGN Financial Highlights
Over the last trailing twelve months DSGN reported a non-GAAP Earnings per Share(EPS) of -0.85. The EPS decreased by 34.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.26% | ||
| ROE | -18.93% | ||
| Debt/Equity | 0 |
DSGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to DSGN. The Buy consensus is the average rating of analysts ratings from 9 analysts.